BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

STK899704 inhibits stemness of cancer stem cells and migration via the FAK-MEK-ERK pathway in HT29 cells

  • Jang, Hui-Ju (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Bak, Yesol (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Pham, Thu-Huyen (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Kwon, Sae-Bom (Department of Bioscience and Biotechnology, Konkuk University) ;
  • Kim, Bo-Yeon (World Class Institute, Anticancer Agents Research Center, Korea Research Institute of Bioscience and Biotechnology) ;
  • Hong, JinTae (College of Pharmacy and Medical Research Center, Chungbuk National University) ;
  • Yoon, Do-Young (Department of Bioscience and Biotechnology, Konkuk University)
  • Received : 2018.08.06
  • Accepted : 2018.09.20
  • Published : 2018.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Colon cancer is one of the most lethal and common malignancies worldwide. STK899704, a novel synthetic agent, has been reported to exhibit anticancer effects towards numerous cancer cells. However, the effect of STK899704 on the biological properties of colon cancer, including cancer cell migration and cancer stem cells (CSCs), remains unknown. Here, we examined the inhibitory effect of STK899704 on cell migration and CSC stemness. In the wound healing assay, STK899704 significantly inhibited the motility of colon cancer cells. Furthermore, STK899704 downregulated the mRNA expression levels of the cell migration mediator focal adhesion kinase (FAK). STK899704 also suppressed mitogen-activated protein kinase kinase and extracellular signal-regulated kinase, which are downstream signaling molecules of FAK. Additionally, STK899704 inhibited stemness gene expression and sphere formation in colon cancer stem cells. These results suggest that STK899704 can be used to treat human colon cancer.

Keywords

References

  1. Siegel R, Naishadham D and Jemal A (2012) Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin 62, 283-298 https://doi.org/10.3322/caac.21153
  2. Lozano R, Naghavi M, Foreman K et al (2012) Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet 380, 2095-2128 https://doi.org/10.1016/S0140-6736(12)61728-0
  3. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D (2011) Global cancer statistics. CA Cancer J Clin 61, 69-90 https://doi.org/10.3322/caac.20107
  4. Bak Y, Kwon T, Bak IS, Hong J, Yu DY and Yoon DY (2016) IL-32theta inhibits stemness and epithelialmesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget 7, 7307-7317
  5. Merika E, Saif MW, Katz A, Syrigos K and Morse M (2010) Review. Colon cancer vaccines: an update. In Vivo 24, 607-628
  6. Bonnet D and Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-737 https://doi.org/10.1038/nm0797-730
  7. Jordan CT (2009) Cancer stem cells: controversial or just misunderstood? Cell Stem Cell 4, 203-205 https://doi.org/10.1016/j.stem.2009.02.003
  8. Lessard J and Sauvageau G (2003) Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423, 255-260 https://doi.org/10.1038/nature01572
  9. Lee HE, Kim JH, Kim YJ et al (2011) An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 104, 1730-1738 https://doi.org/10.1038/bjc.2011.159
  10. Gao XM, Zhang R, Dong QZ and Qin LX (2016) Properties and feasibility of using cancer stem cells in clinical cancer treatment. Cancer Biol Med 13, 489-495 https://doi.org/10.20892/j.issn.2095-3941.2016.0076
  11. Vinogradov S and Wei X (2012) Cancer stem cells and drug resistance: the potential of nanomedicine. Nanomedicine (Lond) 7, 597-615 https://doi.org/10.2217/nnm.12.22
  12. Jordan MA and Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4, 253-265 https://doi.org/10.1038/nrc1317
  13. Zhou J and Giannakakou P (2005) Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 5, 65-71 https://doi.org/10.2174/1568011053352569
  14. Sakchaisri K, Kim SO, Hwang J et al (2017) Anticancer activity of a novel small molecule tubulin inhibitor STK899704. PLoS One 12, e0173311 https://doi.org/10.1371/journal.pone.0173311
  15. Gialeli C, Theocharis AD and Karamanos NK (2011) Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27 https://doi.org/10.1111/j.1742-4658.2010.07919.x
  16. Liang W, Lai Y, Zhu M, Huang S, Feng W and Gu X (2016) Combretastatin A4 regulates proliferation, migration, invasion, and apoptosis of thyroid cancer cells via PI3K/Akt signaling pathway. Med Sci Monit 22, 4911-4917 https://doi.org/10.12659/MSM.898545
  17. McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG and Frame MC (2005) The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 5, 505-515 https://doi.org/10.1038/nrc1647
  18. Pastrana E, Silva-Vargas V and Doetsch F (2011) Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8, 486-498 https://doi.org/10.1016/j.stem.2011.04.007
  19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 100, 3983-3988 https://doi.org/10.1073/pnas.0530291100
  20. Goldman RD (1971) The role of three cytoplasmic fibers in BHK-21 cell motility. I. Microtubules and the effects of colchicine. J Cell Biol 51, 752-762 https://doi.org/10.1083/jcb.51.3.752
  21. Han YS, Lee JH and Lee SH (2015) Fucoidan inhibits the migration and proliferation of HT-29 human colon cancer cells via the phosphoinositide-3 kinase/Akt/mechanistic target of rapamycin pathways. Mol Med Rep 12, 3446-3452 https://doi.org/10.3892/mmr.2015.3804
  22. Mu Y, Zou H, Chen B, Fan Y and Luo S (2017) FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. Biomed Pharmacother 90, 548-554 https://doi.org/10.1016/j.biopha.2017.03.073
  23. Wang YJ, Zhang ZF, Fan SH et al (2017) MicroRNA-433 inhibits oral squamous cell carcinoma cells by targeting FAK. Oncotarget 8, 100227-100241
  24. Deramaudt TB, Dujardin D, Noulet F et al (2014) Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes. PLoS One 9, e92059 https://doi.org/10.1371/journal.pone.0092059
  25. Pylayeva Y, Gillen KM, Gerald W, Beggs HE, Reichardt LF and Giancotti FG (2009) Ras- and PI3K-dependent breast tumorigenesis in mice and humans requires focal adhesion kinase signaling. J Clin Invest 119, 252-266
  26. Schlaepfer DD, Mitra SK and Ilic D (2004) Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta 1692, 77-102 https://doi.org/10.1016/j.bbamcr.2004.04.008
  27. Suva ML, Riggi N, Stehle JC et al (2009) Identification of cancer stem cells in Ewing's sarcoma. Cancer Res 69, 1776-1781 https://doi.org/10.1158/0008-5472.CAN-08-2242
  28. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T and Moriwaki H (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351, 820-824 https://doi.org/10.1016/j.bbrc.2006.10.128
  29. Hurt EM, Kawasaki BT, Klarmann GJ, Thomas SB and Farrar WL (2008) CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis. Br J Cancer 98, 756-765 https://doi.org/10.1038/sj.bjc.6604242
  30. Kim WT and Ryu CJ (2017) Cancer stem cell surface markers on normal stem cells. BMB Rep 50, 285-298 https://doi.org/10.5483/BMBRep.2017.50.6.039
  31. Bak Y, Ham S, Baatartsogt O et al (2013) A1E inhibits proliferation and induces apoptosis in NCI-H460 lung cancer cells via extrinsic and intrinsic pathways. Mol Biol Rep 40, 4507-4519 https://doi.org/10.1007/s11033-013-2544-0
  32. Bak Y, Kang JW, Kim MS et al (2014) IL-32theta downregulates CCL5 expression through its interaction with PKCdelta and STAT3. Cell Signal 26, 3007-3015 https://doi.org/10.1016/j.cellsig.2014.09.015